
25th July 2016

Utilities

Suez

Price EUR14.12

Bloomberg Reuters 12-month High / Low (EUR) Market Cap (EUR) Ev (BG Estimates) (EUR) Avg. 6m daily volume (000) 3y EPS CAGR			SEV FP SEVI.PA 18.3 / 12.9 7,684 18,769 1,268 -2.0%			
	1M 3M			6 M 31/12/15		
Absolute perf.	-1.3%	-12.1%	-15.4%	-18.2%		
Utilities	2.3%	2.8%	3.8%	-0.9%		
DJ Stoxx 600	-0.3%	-2.3%	0.6%	-7.0%		
YEnd Dec. (EURm)	2015	2016e	2017e	2018e		
Sales	15,135	15,456	16,066	16,557		
% change		2.1%	3.9%	3.1%		
EBITDA	2,751	2,653	2,791	2,932		
EBIT	1,381	1,287	1,355	1,459		
% change		-6.8%	5.3%	7.7%		
Net income	559.8	402.8	463.9	527.1		
% change		-28.1%	15.2%	13.6%		
	2015	2016e	2017e	2018e		
Operating margin	9.1	8.3	8.4	8.8		
Net margin	3.7	2.6	2.9	3.2		
ROE	8.2	5.9	6.8	7.7		
ROCE	8.0	7.3	7.5	8.0		
Gearing	121.6	124.2	129.0	132.0		
(EUR)	2015	2016e	2017e	2018e		
EPS	1.04	0.75	0.86	0.98		
% change	-	-28.0%	15.2%	13.6%		
P/E	13.6x	18.9x	16.4x	14.4x		
FCF yield (%)	3.4%	5.6%	4.5%	5.2%		
Dividends (EUR)	0.65	0.65	0.65	0.66		
Div yield (%)	4.6%	4.6%	4.6%	4.7%		
EV/Sales	1.2x	1.2x	1.2x	1.2x		
EV/EBITDA	6.8x	7.1x	6.9x	6.6x		
EV/EBIT	13.6x	14.6x	14.1x	13.3x		



Preview H1 2016: key updates awaited on cost-savings and M&A

Fair Value EUR17.5 (+24%)

Suez is set to report its H1 2016 results on 28th July in the morning. As the macro environment remains challenging for the environmental services company, we do not expect any significant change in Suez's H1 2016 performance. We expect sales to rise slightly in organic terms thanks to a strong performance in the company's international activities, and H1 2016 EBITDA to drop slightly YoY, notably bearing the brunt of a challenging comparable basis and an unfavorable climate which should more than offset cost-savings achieved over the half-year period. We expect the company to give two important updates on its cost-cutting targets (likely to be upgraded, in our view) as well as on its M&A strategy and, a fortiori, on its 2017 EBITDA 'ambition' of EUR3bn, unlikely to be reached as the timing appears too short now for Suez to fully integrate any potential acquisition by 2017. Since we have not included any acquisitions or additional cost-saving measures as yet, we are sticking to our Buy recommendation and maintain our FV at EUR17.5.

BUY

ANALYSIS

- What to expect from Suez' H1 2016 publication? As the global macro environment remains challenging (no significant industrial recovery in Europe, low inflation environment in mature markets), we do not expect any significant inflexion in Suez's Q2 2016 results compared to the company's first quarter performance. We expect H1 2016 revenues to reach EUR7,340m, slightly up 0.6% YoY - despite a 1.3% FX headwind - spurred by a strong performance in Suez's international business division (8.6% organic growth) which should more than offset poor performance in both the Water Europe and Waste Europe segments (+0.3% and -0.8% organically YoY, respectively). On top of a challenging H1 2015 comparable base, we expect Water Europe to bear the brunt of 1) the low inflation environment in Europe; 2) loss of the Lille contract; 3) the unfavorable climate in Chile on top of a flood in one of the company's plants, which should have a negative impact on volumes and the division's EBITDA (low single digit negative impact). As for the waste business, we expect sales to be penalised by the drop in raw materials prices as well as by flattish volumes due to still spluttering industrial production in Europe. We expect the division's H1 2016 EBITDA to drop 0.8% YoY in organic terms, notably due to a EUR19m headwind attributable to the drop in electricity prices (EUR11m in Q1 2016 and EUR8m in Q2 2016). In all, after a 0.1% organic decline in Q1 2016, we expect the company's EBITDA to reach EUR1.263bn in H1 2016 (-0.6% organically YoY) implying a 17.2% EBITDA margin over the half-year period, 50bp below last year's performance. We expect H1 2016 EBIT to reach EUR571m (vs. EUR604m in H1 2015) and net income of EUR147m (vs. EUR141m last year) as we expect a lower minorities impact (EUR95m vs. EUR111m).
- Updates awaited on M&A and cost-reductions: During the H1 2016 results presentation, we expect Suez to give an update on its M&A strategy as well on its initial EUR3bn EBITDA 'ambition' for FY 2017e. As the timing now looks too short for Suez to fully integrate any potential acquisition, we think the company is unlikely to reach this target, which was to be delivered through both organic growth and M&A (c. EUR200m each). As we believe this is already well priced-in (Suez's share price is down c. 18% YTD - vs. -2.6% for the Stoxx 600 Utilities and -11% for Veolia Environnement - while the consensus currently stands at EUR2,769 vs. EUR2,791m for BG, both well below EUR3bn), we do not expect any significant derating in case of a downgrade to this target. However, we believe any indication below EUR2.800bn would be negatively received by the market as this would imply an organic contribution lower than the c. EUR200m currently anticipated. Despite the still spluttering macro environment, we believe Suez is likely to guide over EUR2.800bn for FY 2017e as we expect the company to announce additional cost-saving measures during its H1 2016 results. Since 2010, Suez has a solid track record in delivering costsavings. For each of the last five years, the company has upgraded its initial cost-savings target and/or has exceeded it. We believe Suez is likely to upgrade its target this year again. In our recent report (Haste makes waste, it's upside time !), we estimate that additional EUR90m-EUR100m procurement savings - spread over 2016/2017/2018 - would increase our FV by EUR0.3.

VALUATION

- At the current share price, Suez is trading at 7.1x its 2016e EBITDA
- Buy, FV @ 17.5

Table 1: H1 2016 key metrics

Suez - Preview	H1 2016e	H1 2015
Revenues	7,340	7,295
YoY change	0.6%	-
o/w organic	1.9%	-
o/w FX	-1.3%	-
o/w Water	2226	2261
YoY change	-1.5%	-
o/w organic	0.3%	-
o/w Waste	3,120	3,167
YoY change	-1.5%	-
o/w organic	-0.8%	-
o/w International	1,942	1,815
YoY change	7.0%	-
o/w organic	8.6%	-
EBITDA	1,263	1,293
EBITDA margin	17.2%	17.7%
o/w organic	-0.6%	-
o/w FX	-1.7%	-
o/w Water	622	662
o/w Waste	362	368
o/w International	317	303

Source : Company Data; Bryan Garnier & Co. ests.

Table 2: Summarised P&L

P&L -Suez	H1-16e	H1-15
Revenues	7,340	7,295
EBITDA	1,263	1,293
D&A	(557)	(556)
Concessions charges	(132)	(137)
Others	(3)	4
EBIT	571	604
Rebranding costs	(18)	(18)
Restructuring costs	(25)	(28)
Others	(40)	(56)
Income from. Op Activities	489	502
Cost of net debt	(197)	(200)
Taxes	(50)	(50)
Minorities	(95)	(111)
Net income, Group share	147	141

Source : Company Data; Bryan Garnier & Co. ests.

Click here to download document

Analyst : Pierre-Antoine Chazal 33(0) 1.56.68.75.06 pachazal@bryangarnier.com Sector Team : Xavier Caroen

BRYAN, GARNIER & CO

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

DIN	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a			
BUY	recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of			
	elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock			
	will feature an introduction outlining the key reasons behind the opinion.			

- NEUTRAL Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
- SELL Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 55%

NEUTRAL ratings 34.2%

SELL ratings 10.7%

Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer		
2	Issuer shareholding in Bryan Garnier	Bryan The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more member of the Bryan Garnier Group.	
3	Financial interest	st A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	
5	Lead/co-lead manager	Lead/co-lead manager In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	
6	Investment banking agreement A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with t Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.		No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

BRYAN, GARNIER & CO

London	Paris	New York	Munich	New Delhi	
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	Widenmayerstrasse 29	The Imperial Hotel Janpath	
15 St. Botolph Street	75008 Paris	New York, NY 10022	80538 Munich	New Delhi 110 001 Tel +91 11 4132 6062	
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Germany	+91 98 1111 5119	
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	+49 89 2422 62 11	Fax +91 11 2621 9062	
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member		Geneva	
Authorised and regulated by the	nancial Conduct Authority (FCA) and the			rue de Grenus 7 CP 2113	
Financial Conduct Authority (FCA)	Autorité de Contrôle prudential et de			Genève 1, CH 1211	
	resolution (ACPR)			Tel +4122 731 3263	

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Fax+4122731 3243 Regulated by the FINMA

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited intervent on it for any purposes whatsoever.

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not

aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available..

BRYAN, GARNIER & CO